Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study.
Publication
, Conference
Erba, HP; Levis, MJ; Sekeres, MA; Dombret, H; Amadori, S; Zernovak, O; Mires, DE; Ge, N; Hanyok, J; Macintyre, S; Gokmen, S; Gammon, G; Schlenk, RF
Published in: Journal of Clinical Oncology
May 20, 2016
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
TPS7073 / TPS7073
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Levis, M. J., Sekeres, M. A., Dombret, H., Amadori, S., Zernovak, O., … Schlenk, R. F. (2016). Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. In Journal of Clinical Oncology (Vol. 34, pp. TPS7073–TPS7073). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.tps7073
Erba, Harry Paul, Mark J. Levis, Mikkael A. Sekeres, Herve Dombret, Sergio Amadori, Oleg Zernovak, Derek Edward Mires, et al. “Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study.” In Journal of Clinical Oncology, 34:TPS7073–TPS7073. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps7073.
Erba HP, Levis MJ, Sekeres MA, Dombret H, Amadori S, Zernovak O, et al. Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS7073–TPS7073.
Erba, Harry Paul, et al. “Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. TPS7073–TPS7073. Crossref, doi:10.1200/jco.2016.34.15_suppl.tps7073.
Erba HP, Levis MJ, Sekeres MA, Dombret H, Amadori S, Zernovak O, Mires DE, Ge N, Hanyok J, Macintyre S, Gokmen S, Gammon G, Schlenk RF. Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-First study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. TPS7073–TPS7073.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
TPS7073 / TPS7073
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences